Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.17
XRAY's Cash-to-Debt is ranked lower than
84% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. XRAY: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
XRAY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.07 Max: No Debt
Current: 0.17
Equity-to-Asset 0.67
XRAY's Equity-to-Asset is ranked higher than
64% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. XRAY: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
XRAY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.52 Max: 0.8
Current: 0.67
0.22
0.8
Debt-to-Equity 0.22
XRAY's Debt-to-Equity is ranked higher than
64% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. XRAY: 0.22 )
Ranked among companies with meaningful Debt-to-Equity only.
XRAY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 0.47 Max: 2.19
Current: 0.22
0.07
2.19
Piotroski F-Score: 5
Altman Z-Score: 2.85
Beneish M-Score: -3.15
WACC vs ROIC
10.17%
-8.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -18.29
XRAY's Operating Margin % is ranked higher than
67% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. XRAY: -18.29 )
Ranked among companies with meaningful Operating Margin % only.
XRAY' s Operating Margin % Range Over the Past 10 Years
Min: -18.29  Med: 14.73 Max: 17.66
Current: -18.29
-18.29
17.66
Net Margin % -20.57
XRAY's Net Margin % is ranked higher than
66% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. XRAY: -20.57 )
Ranked among companies with meaningful Net Margin % only.
XRAY' s Net Margin % Range Over the Past 10 Years
Min: -20.57  Med: 11.27 Max: 12.94
Current: -20.57
-20.57
12.94
ROE % -9.84
XRAY's ROE % is ranked lower than
53% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. XRAY: -9.84 )
Ranked among companies with meaningful ROE % only.
XRAY' s ROE % Range Over the Past 10 Years
Min: -9.84  Med: 13.89 Max: 18.61
Current: -9.84
-9.84
18.61
ROA % -6.88
XRAY's ROA % is ranked higher than
50% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. XRAY: -6.88 )
Ranked among companies with meaningful ROA % only.
XRAY' s ROA % Range Over the Past 10 Years
Min: -6.88  Med: 6.55 Max: 10.69
Current: -6.88
-6.88
10.69
ROC (Joel Greenblatt) % -45.70
XRAY's ROC (Joel Greenblatt) % is ranked higher than
77% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. XRAY: -45.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XRAY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -45.7  Med: 38.16 Max: 54.55
Current: -45.7
-45.7
54.55
3-Year Revenue Growth Rate -6.00
XRAY's 3-Year Revenue Growth Rate is ranked lower than
76% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. XRAY: -6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XRAY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6  Med: 11.9 Max: 42.9
Current: -6
-6
42.9
3-Year EBITDA Growth Rate -3.60
XRAY's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. XRAY: -3.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XRAY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22.4  Med: 9.5 Max: 50.5
Current: -3.6
-22.4
50.5
3-Year EPS without NRI Growth Rate -3.50
XRAY's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. XRAY: -3.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XRAY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.9  Med: 11 Max: 88.3
Current: -3.5
-32.9
88.3
GuruFocus has detected 1 Warning Sign with Dentsply Sirona Inc $XRAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XRAY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

XRAY Guru Trades in Q3 2016

Andreas Halvorsen 694,607 sh (New)
Paul Tudor Jones 8,243 sh (+83.18%)
Ruane Cunniff 8,163,402 sh (+73.50%)
Chuck Royce 69,000 sh (+4.55%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Mario Gabelli 125,310 sh (-0.71%)
Jim Simons 180,458 sh (-1.20%)
Columbia Wanger 614,039 sh (-20.08%)
Ray Dalio 4,500 sh (-25.00%)
» More
Q4 2016

XRAY Guru Trades in Q4 2016

Pioneer Investments 877,100 sh (New)
Andreas Halvorsen 1,680,154 sh (+141.89%)
Jim Simons 301,858 sh (+67.27%)
Ruane Cunniff 9,102,714 sh (+11.51%)
Chuck Royce 75,900 sh (+10.00%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 121,210 sh (-3.27%)
Columbia Wanger 516,159 sh (-15.94%)
» More
Q1 2017

XRAY Guru Trades in Q1 2017

Steven Cohen 1,027,933 sh (New)
Jim Simons 1,044,558 sh (+246.04%)
Chuck Royce 102,650 sh (+35.24%)
Pioneer Investments 884,680 sh (+0.86%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Ruane Cunniff 8,721,237 sh (-4.19%)
Mario Gabelli 114,210 sh (-5.78%)
Columbia Wanger 458,186 sh (-11.23%)
Andreas Halvorsen 854,398 sh (-49.15%)
» More
Q2 2017

XRAY Guru Trades in Q2 2017

Paul Tudor Jones 7,613 sh (New)
Joel Greenblatt 78,828 sh (New)
Andreas Halvorsen 1,430,369 sh (+67.41%)
Pioneer Investments 1,301,449 sh (+47.11%)
Chuck Royce 126,650 sh (+23.38%)
Ruane Cunniff 8,849,888 sh (+1.48%)
Mario Gabelli 114,210 sh (unchged)
Jim Simons Sold Out
Steven Cohen 946,100 sh (-7.96%)
Vanguard Health Care Fund 1,453,190 sh (-23.70%)
Columbia Wanger 294,726 sh (-35.68%)
» More
» Details

Insider Trades

Latest Guru Trades with XRAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ruane Cunniff 2017-06-30 Add 1.48%0.08%$61.35 - $65.59 $ 58.48-7%8,849,888
Vanguard Health Care Fund 2017-06-30 Reduce -23.70%0.06%$61.35 - $65.59 $ 58.48-7%1,453,190
Joel Greenblatt 2017-06-30 New Buy0.07%$61.35 - $65.59 $ 58.48-7%78,828
Ruane Cunniff 2017-03-31 Reduce -4.19%0.21%$55.59 - $64.5 $ 58.48-3%8,721,237
Mario Gabelli 2017-03-31 Reduce -5.78%$55.59 - $64.5 $ 58.48-3%114,210
Ruane Cunniff 2016-12-31 Add 11.51%0.51%$55.83 - $61.19 $ 58.48-1%9,102,714
Mario Gabelli 2016-12-31 Reduce -3.27%$55.83 - $61.19 $ 58.48-1%121,210
Ruane Cunniff 2016-09-30 Add 73.50%1.93%$58.83 - $65.14 $ 58.48-5%8,163,402
Mario Gabelli 2016-09-30 Reduce -0.71%$58.83 - $65.14 $ 58.48-5%125,310
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339114    SIC: 3843
Compare:NYSE:WAT, NYSE:COO, NYSE:RMD, NYSE:MTD, NAS:HOLX, NYSE:WST, NYSE:HRC, NYSE:BCR, NAS:ICUI, NYSE:CMD, NAS:PODD, NYSE:HAE, NYSE:HYH, NAS:MMSI, NAS:NXTM, NAS:OSUR, NAS:ATRI, NAS:IRTC, NYSE:GKOS, NAS:LMNX » details
Traded in other countries:XRAY.Austria, DY2.Germany,
Headquarter Location:USA
Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. It also manufactures and markets other consumable medical device products.

Dentsply Sirona is one of the world's largest manufacturers and distributors of dental supplies and equipment. Its product segments include dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. Over half of its products are sold through dental distributors, and approximately 65% of Dentsply's sales are outside the U.S.

Guru Investment Theses on Dentsply Sirona Inc

Ruane Cunniff Comments on Dentsply Sirona - Oct 13, 2016

After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of performance.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund third quarter 2016 letter to shareholders.

Check out Ruane Cunniff latest stock trades

Top Ranked Articles about Dentsply Sirona Inc

Harwood Feffer LLP Announces Investigation of DENTSPLY SIRONA Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DENTSPLY SIRONA Inc. - XRAY
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dentsply Sirona, Inc. (XRAY)
Dentsply Sirona to Report Second Quarter 2017 Results on August 9th
Dentsply Sirona Declares Quarterly Cash Dividend
Dentsply Sirona Expands and Extends Relationship with Pacific Dental Services, LLC
Dentsply Sirona to Report First Quarter 2017 Results on May 9
Ruane Cunniff Makes One Significant Buy Sequoia Fund enters dental space after disposing of Valeant
On Tuesday, Ruane Cunniff (Trades, Portfolio) disclosed its first quarterly update since losing significantly on a position in Valeant Pharmaceuticals (NYSE:VRX), a fast-growing drug maker accused of price gouging and a dubious relationship with a pharmacy. The firm’s Sequoia Fund made only one large purchase during the third quarter, Dentsply Sirona (NASDAQ:XRAY). Read more...
Ruane Cunniff Comments on Dentsply Sirona Guru stock highlight
After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 19.27
XRAY's Forward PE Ratio is ranked higher than
76% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. XRAY: 19.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.86
XRAY's PB Ratio is ranked higher than
76% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. XRAY: 1.86 )
Ranked among companies with meaningful PB Ratio only.
XRAY' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.71 Max: 4.65
Current: 1.86
1.58
4.65
PS Ratio 3.54
XRAY's PS Ratio is ranked lower than
55% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. XRAY: 3.54 )
Ranked among companies with meaningful PS Ratio only.
XRAY' s PS Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.41 Max: 3.99
Current: 3.54
1.58
3.99
Price-to-Free-Cash-Flow 31.47
XRAY's Price-to-Free-Cash-Flow is ranked lower than
53% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.92 vs. XRAY: 31.47 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
XRAY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.38  Med: 19.74 Max: 35.01
Current: 31.47
12.38
35.01
Price-to-Operating-Cash-Flow 23.41
XRAY's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. XRAY: 23.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
XRAY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.42  Med: 15.35 Max: 26.51
Current: 23.41
10.42
26.51
EV-to-EBIT -21.05
XRAY's EV-to-EBIT is ranked lower than
75% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. XRAY: -21.05 )
Ranked among companies with meaningful EV-to-EBIT only.
XRAY' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.2  Med: 18.6 Max: 39.2
Current: -21.05
-23.2
39.2
EV-to-EBITDA -37.22
XRAY's EV-to-EBITDA is ranked lower than
59% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. XRAY: -37.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
XRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41  Med: 14.55 Max: 27.1
Current: -37.22
-41
27.1
EV-to-Revenue 3.84
XRAY's EV-to-Revenue is ranked lower than
55% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. XRAY: 3.84 )
Ranked among companies with meaningful EV-to-Revenue only.
XRAY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 2.8 Max: 5.2
Current: 3.84
1.7
5.2
Shiller PE Ratio 37.52
XRAY's Shiller PE Ratio is ranked higher than
73% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. XRAY: 37.52 )
Ranked among companies with meaningful Shiller PE Ratio only.
XRAY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.1  Med: 25.71 Max: 44.86
Current: 37.52
18.1
44.86
Current Ratio 2.34
XRAY's Current Ratio is ranked lower than
56% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. XRAY: 2.34 )
Ranked among companies with meaningful Current Ratio only.
XRAY' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.88 Max: 4.36
Current: 2.34
1.2
4.36
Quick Ratio 1.55
XRAY's Quick Ratio is ranked lower than
58% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. XRAY: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
XRAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.06 Max: 2.98
Current: 1.55
0.63
2.98
Days Inventory 114.90
XRAY's Days Inventory is ranked higher than
60% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. XRAY: 114.90 )
Ranked among companies with meaningful Days Inventory only.
XRAY' s Days Inventory Range Over the Past 10 Years
Min: 89.71  Med: 101.08 Max: 114.9
Current: 114.9
89.71
114.9
Days Sales Outstanding 63.07
XRAY's Days Sales Outstanding is ranked higher than
58% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. XRAY: 63.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
XRAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.12  Med: 56.27 Max: 63.07
Current: 63.07
53.12
63.07
Days Payable 51.15
XRAY's Days Payable is ranked higher than
53% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. XRAY: 51.15 )
Ranked among companies with meaningful Days Payable only.
XRAY' s Days Payable Range Over the Past 10 Years
Min: 31.01  Med: 37.45 Max: 51.15
Current: 51.15
31.01
51.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.56
XRAY's Dividend Yield % is ranked lower than
81% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. XRAY: 0.56 )
Ranked among companies with meaningful Dividend Yield % only.
XRAY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.54 Max: 0.85
Current: 0.56
0.35
0.85
3-Year Dividend Growth Rate 7.40
XRAY's 3-Year Dividend Growth Rate is ranked lower than
56% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. XRAY: 7.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
XRAY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.6 Max: 37.5
Current: 7.4
0
37.5
Forward Dividend Yield % 0.61
XRAY's Forward Dividend Yield % is ranked lower than
83% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. XRAY: 0.61 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.85
XRAY's 5-Year Yield-on-Cost % is ranked lower than
74% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. XRAY: 0.85 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
XRAY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.53  Med: 0.82 Max: 1.3
Current: 0.85
0.53
1.3
3-Year Average Share Buyback Ratio -17.40
XRAY's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. XRAY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XRAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.6  Med: 0.3 Max: 2.2
Current: -17.4
-67.6
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.44
XRAY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. XRAY: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
XRAY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.49 Max: 7.53
Current: 1.44
0.99
7.53
Price-to-Median-PS-Value 1.47
XRAY's Price-to-Median-PS-Value is ranked lower than
75% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. XRAY: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XRAY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.88 Max: 1.63
Current: 1.47
0.36
1.63
Earnings Yield (Greenblatt) % -4.75
XRAY's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. XRAY: -4.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XRAY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.2  Med: 5.3 Max: 10.4
Current: -4.75
-5.2
10.4
Forward Rate of Return (Yacktman) % 5.21
XRAY's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. XRAY: 5.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
XRAY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.5  Med: 10.3 Max: 31.1
Current: 5.21
-3.5
31.1

More Statistics

Revenue (TTM) (Mil) $3,843.90
EPS (TTM) $ -3.47
Beta1.46
Short Percentage of Float3.35%
52-Week Range $52.54 - 65.68
Shares Outstanding (Mil)229.50

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,958 4,130 4,287
EPS ($) 2.68 2.97 3.11
EPS without NRI ($) 2.68 2.97 3.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.81%
Dividends per Share ($) 0.33 0.33 0.39
» More Articles for XRAY

Headlines

Articles On GuruFocus.com
Harwood Feffer LLP Announces Investigation of DENTSPLY SIRONA Inc. Aug 18 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DENTSPLY SIRONA Aug 10 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dentsply Sirona, In Aug 10 2017 
Dentsply Sirona to Report Second Quarter 2017 Results on August 9th Aug 01 2017 
5 Companies Reach 52-Week Highs Jul 18 2017 
Dentsply Sirona Declares Quarterly Cash Dividend Jun 22 2017 
Dentsply Sirona Expands and Extends Relationship with Pacific Dental Services, LLC Jun 16 2017 
Dentsply Sirona Expected to Leap in EPS May 08 2017 
Dentsply Sirona to Report First Quarter 2017 Results on May 9 May 03 2017 
Ruane Cunniff Makes One Significant Buy Oct 14 2016 

More From Other Websites
DENTSPLY SIRONA, Inc. breached its 50 day moving average in a Bullish Manner : XRAY-US : September... Sep 18 2017
ETFs with exposure to DENTSPLY SIRONA, Inc. : September 14, 2017 Sep 13 2017
New Strong Sell Stocks for September 12th Sep 12 2017
DENTSPLY SIRONA, Inc. :XRAY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Sep 11 2017
See what the IHS Markit Score report has to say about DENTSPLY SIRONA Inc. Sep 11 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of DENTSPLY SIRONA Inc. and... Aug 18 2017
Harwood Feffer LLP Announces Investigation of DENTSPLY SIRONA Inc. Aug 18 2017
Discussing Dentsply Sirona’s Recent Stock Performance Aug 17 2017
What Do Analysts Recommend for Dentsply Sirona? Aug 17 2017
Featured Company News - NeuroMetrix Announces Issuance of New US Patent for Automated Control of... Aug 17 2017
Discussing Dentsply Sirona’s Updated 2017 Guidance Aug 17 2017
Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17 Aug 16 2017
New Strong Sell Stocks for August 16th Aug 16 2017
Dental and Healthcare Consumables Grew but Missed Expectations in 2Q17 Aug 16 2017
Dentsply Sirona’s 2Q17 Results: Key Highlights Aug 16 2017
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of DENTSPLY SIRONA Inc. Aug 14 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Dentsply Sirona,... Aug 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}